Furthermore, tertiary lymphoid structures (TLS), which target endogenously retroviruses and are protective in vivo, are predictive for response to immunotherapy as demonstrated by a stimulation of anti-tumor B cell responses upon KRAS inhibition. This evidence concerns the gene KRAS and neoplasm.